Xenon Pharmaceuticals Inc. (XENE)
After hours:
| Previous Close | 43.19 |
| Open | 43.40 |
| Bid | 43.38 x 100 |
| Ask | 43.54 x 100 |
| Day's Range | 42.65 - 43.60 |
| 52 Week Range | 27.99 - 50.99 |
| Volume | |
| Avg. Volume | 364,119 |
| Market Cap | 3.277B |
| Beta (5Y Monthly) | 1.18 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.73 |
| Earnings Date | May 09, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 58.10 |
GlobeNewswireXenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference
VANCOUVER, British Columbia, May 07, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the 2024 RBC Capital Markets Global Healthcare Conference taking place May 14-15, 2024 in New York, NY. Fireside Chat Presentation Details: Date:Tuesday, May 14, 2024Time:3:35 pm Eastern TimeWebcast:Register herePresenters:Ian Mortimer, President and Chief Executive OfficerSherry Aulin, Chief Fin
ZacksWhat Makes Xenon Pharmaceuticals (XENE) a New Buy Stock
Xenon Pharmaceuticals (XENE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- GlobeNewswire
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update
VANCOUVER, British Columbia, May 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced it will report its first quarter 2024 financial and operating results after the close of U.S. financial markets on Thursday, May 9, 2024. Conference Call/Webcast Information: Date:Thursday, May 9, 2024 Time:4:30 pm Eastern Time (1:30 pm Pacific Time) Webcast:Pre-register here Dial-In: (800) 715-9871 toll-free, or (646) 307-1963
